Brigatinib (Brigatinib) research and development background, market price and purchasing guide

Brigatinib (Brigatinib), trade name: Amberly, is an innovative drug mainly used to treat ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC). The drug was originally developed by Ariad and received accelerated approval from the US FDA in April 2017. In February 2017, Takeda acquired Ariad at a high price, thus gaining ownership of this lung cancer drug. Brigatinib was approved for marketing by the National Medical Products Administration in China in March 2022, providing a new treatment option for Chinese ALK-positive NSCLC patients.

Brigatinib is an ALK tyrosine kinase inhibitor that slows down or prevents the proliferation of cancer cells by inhibiting the activity of ALK receptors. Clinical data shows that brigatinib has significant efficacy in prolonging patient survival, controlling brain metastases, and improving quality of life. Especially in patients with NSCLC who are resistant to the first-generation ALK inhibitor crizotinib, brigatinib has shown breakthrough efficacy. In addition, brigatinib has been granted orphan drug status by the FDA for the treatment of NSCLC patients who are resistant to first-generation ALK inhibitors.

In terms of market price, the price of brigatinib is relatively high. According to the latest information, in the domestic market, a box of drugs with a specification of 30 mg * 28 tablets is priced at about two to three thousand yuan, and a box of drugs with a specification of 90 mg * 28 tablets is sold at about five or six thousand yuan.

When purchasing brigatinib, patients can do so through a variety of channels. First, brigatinib may be available in pharmacies of some large hospitals, and patients can consult local hospitals for purchasing information. Secondly, some professional oncology pharmacies may sell brigatinib, but the quantity is limited. In addition, patients can also purchase drugs through online drug purchase platforms, but they must pay attention to verify the authenticity of the drugs. Finally, due to the relatively high price of brigatinib in China, some patients may choose to purchase generic drugs overseas, but they should choose drug purchasing channels carefully to avoid purchasing fake and shoddy products.

In short, brigatinib, as an innovative drug, provides new treatment hope forALK-positive NSCLC patients. When purchasing, patients should pay attention to the authenticity, price, and reliability of the purchasing channel to ensure the safety and effectiveness of the drug.